CCG
REGN icon

Capital CS Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Capital CS Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-392
Closed -$322K – 102
2023
Q1 		$322K Buy
+392
New +$296K 0.3% 36
2021
Q4 		– Sell
-1,130
Closed -$645K – 88
2021
Q3 		$645K Buy
+1,130
New +$702K 0.6% 33

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital CS Group's REGN Position: Q2 2023 in Review

Capital CS Group sold out of Regeneron Pharmaceuticals (REGN) in Q2 2023, closing a stake of 392 shares — an estimated $322K sold.

Capital CS Group first reported a position in REGN in Q3 2021 and held it in 2 quarters. The position peaked at $645K in Q3 2021. 1,164 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

  • Capital CS Group reported no remaining Regeneron Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Capital CS Group sold 392 Regeneron Pharmaceuticals shares in Q2 2023, an estimated $322K.
  • Capital CS Group first reported a position in Regeneron Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Capital CS Group's Regeneron Pharmaceuticals position peaked at $645K in Q3 2021.
  • 1,164 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on Capital CS Group's 13F filing for Q2 2023, filed 11 Jul 2023.